Sanofi Stumbles as Key Medicines' Sales Spark Growth Concerns
- Dupixent, Toujeo quarterly sales miss analysts’ estimates
- Sanofi shares decline as much as 2% in Paris trading
This article is for subscribers only.
A handful of Sanofi’s top drugs stumbled in the first quarter, sparking concern about growth as the French drugmaker attempts to become a leader in blood disorders via $16 billion in acquisitions.
The stock fell as much as 2 percent in Paris trading after the company reported declining profit and revenue for the quarter and pointed to a new period of expansion starting in the second half.